Major Study Affirming the Relative Safety of Testosterone-replacement Therapy

Bruce Biundo1

  • 1Professional Compounding Centers of America. bbrxman@aol.com.

Insights

Testosterone replacement therapy is safe for men with low testosterone and cardiovascular disease. A major study found it poses no greater cardiovascular risk than a placebo.

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Men's Health

Background:

  • Concerns exist regarding cardiovascular risks of testosterone replacement therapy (TRT).
  • Hypogonadal men with symptoms are often undertreated due to safety concerns.
  • Existing research has yielded conflicting results on TRT's cardiovascular safety.

Purpose of the Study:

  • To evaluate the cardiovascular safety of TRT in men with established cardiovascular disease or at high risk.
  • To determine if TRT increases adverse cardiovascular events compared to placebo.

Main Methods:

  • A large-scale research project involving men with cardiovascular disease or high cardiovascular risk.
  • Comparison of TRT group versus placebo group.
  • Monitoring of major adverse cardiovascular events.

Main Results:

  • Testosterone replacement therapy was found to be non-inferior to placebo regarding cardiovascular safety.
  • No significant increase in cardiovascular events was observed in men receiving TRT.
  • The therapy did not worsen outcomes for men with pre-existing cardiovascular conditions.

Conclusions:

  • TRT can be considered a safe option for hypogonadal men with cardiovascular disease or at high risk.
  • The study alleviates concerns about TRT's cardiovascular safety in this patient population.
  • This finding supports improved quality of life for hypogonadal men through safe TRT.

Related Concept Videos

Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
700
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
434
Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.3K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
48